{{refimprove|date=October 2017}}
{{Drugbox
| verifiedrevid = 460033034
| IUPAC_name = 6-chloro-1,1-dioxo-2''H''-1,2,4-benzothiadiazine-7-sulfonamide
| image = Chlorothiazide.svg
| image2 = Chlorothiazide-from-xtal-3D-balls.png
<!--Clinical data-->
| tradename = Diuril
| Drugs.com = {{drugs.com|monograph|chlorothiazide}}
| MedlinePlus = a682341
| pregnancy_US = C
| legal_US = Rx-only
| routes_of_administration = Oral, IV
<!--Pharmacokinetic data-->
| bioavailability =  low
| metabolism = Nil
| elimination_half-life = 45 to 120 minutes
| excretion = [[Kidney|Renal]]
<!--Identifiers-->
| IUPHAR_ligand = 4835
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 58-94-6
| ATC_prefix = C03
| ATC_suffix = AA04
| PubChem = 2720
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00880
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2619
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 77W477J15H
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00519
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 3640
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 842
<!--Chemical data-->
| C=7 | H=6 | Cl=1 | N=3 | O=4 | S=2
| molecular_weight = 295.72 g/mol
| smiles = O=S(=O)(c1c(Cl)cc2c(c1)S(=O)(=O)/N=C\N2)N
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C7H6ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-3H,(H,10,11)(H2,9,12,13)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = JBMKAUGHUNFTOL-UHFFFAOYSA-N
}}
'''Chlorothiazide sodium''' ('''Diuril''') is an [[organic compound]] used as a [[diuretic]] and as an [[antihypertensive]].<ref>Ernst, Michael E.; Grimm, Richard H., Jr. "Thiazide diuretics: 50 years and beyond" Current Hypertension Reviews 2008, volume 4(4), pp. 256-265. {{DOI|10.2174/157340208786241264}}</ref>

It is used both within the hospital setting or for personal use to manage excess fluid associated with [[congestive heart failure]].  
Most often taken in pill form, it is usually taken orally once or twice a day. In the [[Intensive Care Unit|ICU]] setting, chlorothiazide is given to diurese a patient in addition to [[furosemide]] (Lasix). Working in a separate mechanism than furosemide, and absorbed enterically as a reconstituted suspension administered through a [[nasogastric intubation|nasogastric tube]] (NG tube), the two drugs potentiate one another.

It was discovered in 1957.<ref name=Wal2012>{{cite book|last1=Walker|first1=S. R.|title=Trends and Changes in Drug Research and Development|date=2012|publisher=Springer Science & Business Media|isbn=9789400926592|page=109|url=https://books.google.ca/books?id=FB_2CAAAQBAJ&pg=PA109|language=en}}</ref>

== Indications ==
* Large amount of excess fluid including:
**Diagnosed [[congested heart failure]]
**[[Peripheral edema]]
**[[Rales]] / [[Rhonchi]]
**[[Hypertension]]

== Contraindications ==
* [[Renal failure]] or insufficiency
* [[Allergies]] to [[sulfa drug]]s

== Side effects ==
* [[Nausea]] / [[Vomiting]]
* [[Headache]]
* [[Dizziness]]
* [[Polyuria|Excess urine production]]
* [[Dehydration]]
* [[Electrolyte disturbance|Hypoelectrolytemia]] (esp. [[hypokalemia]] / [[hypomagnesia]])

== History ==
The Research team of Merck Sharp and Dohme Research Laboratories of Beyer, Sprague, Baer, and Novello created a new series of medications, the thiazide diuretics, which includes chlorothiazide.  They won an Albert Lasker Special Award in 1975 for this work.<ref>{{cite web|url=http://www.laskerfoundation.org/awards/formaward.htm|title=Historical Awards - The Lasker Foundation|first=Lasker|last=Foundation|website=The Lasker Foundation}}</ref>

==References==
{{reflist}}

{{Diuretics}}

[[Category:Thiazides]]
[[Category:Benzothiadiazines]]
[[Category:Sulfonamides]]
[[Category:Carbonic anhydrase inhibitors]]
[[Category:World Anti-Doping Agency prohibited substances]]